Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

MLA

Vogelzang, Nicholas, et al. “Carboplatin in Malignant Mesothelioma: A Phase II Study of the Cancer and Leukemia Group B.” Cancer Chemotherapy & Pharmacology, vol. 27, no. 3, Dec. 1990, pp. 239–42. EBSCOhost, https://doi.org/10.1007/BF00685720.

APA

Vogelzang, N., Goutsou, M., Corson, J., Suzuki, Y., Graziano, S., Aisner, J., Cooper, M., Coughlin, K., Green, M., Vogelzang, N. J., Goutsou, M., Corson, J. M., Suzuki, Y., Graziano, S., Aisner, J., Cooper, M. R., Coughlin, K. M., & Green, M. R. (1990). Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemotherapy & Pharmacology, 27(3), 239–242. https://doi.org/10.1007/BF00685720

Chicago

Vogelzang, Nicholas, Maria Goutsou, Joseph Corson, Yasunosuke Suzuki, Stephen Graziano, Joseph Aisner, M. Cooper, et al. 1990. “Carboplatin in Malignant Mesothelioma: A Phase II Study of the Cancer and Leukemia Group B.” Cancer Chemotherapy & Pharmacology 27 (3): 239–42. doi:10.1007/BF00685720.